Latest News

Ablative treatment of metastases in prostate cancer is an emerging therapeutic approach. The aim is to complement, replace or delay the introduction of hormone therapy or other systemic therapies with palliative intent and associated with systemic side effects. Additionally, metastases ablation can avoid metastases-to-metastases spread1, source of tumor progression. The different methods of achieving an […]

This article is one of several emanating from a session during the 33rd Annual EAU Congress. The session focused on problems in bladder cancer, that while important and common, remain controversial. Each of the clinical challenges began with a case presentation highlighting the problem followed by two alternate paths for a clinical resolution presented by […]

Prior to the approval of nivolumab, a monoclonal antibody targeting programmed death-1 (PD-1), vascular endothelial growth factor-receptor tyrosine kinase inhibitors (VEGFR-TKIs), specifically pazopanib and sunitinib, were the standard of care in the front-line setting for metastatic clear cell renal cell carcinoma (mccRCC). CheckMate 025, a randomized, open label, phase 3 study comparing nivolumab to everolimus […]

We evaluated the gastrin-releasing peptide receptor antagonist probe 68Ga-RM2 with PET/CT imaging for localization of newly diagnosed prostate cancer.1 Gastrin-releasing peptide receptor is one of the 4 known bombesin receptors overexpressed in prostate cancer.2 For that, we prospectively studied 16 men with biopsy-proven prostate cancer (2 low, 8 intermediate and 6 high risk). 68Ga-RM2 PET/CT […]

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Intervention: Drug: Niraparib 200 mg Drug: JNJ-63723283 240 mg Drug: JNJ-63723283 480 mg Drug: Abiraterone Acetate Drug: Prednisone Purpose: The purpose of this study is to establish the recommended phase 2 dose (RP2D) of niraparib […]

Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations Condition: Cholangiocarcinoma, Brain Tumor, Urothelial Cancer, Other Tumor Types With FGFR2 Gene Fusions, Activating Mutations, FGFR2 Amplification Intervention: Drug: TAS-120 Purpose: This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose […]

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Condition: Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortex Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Cervical Adenocarcinoma, Cervical Clear Cell Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal […]

My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents Condition: Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer Intervention: Drug: Trastuzumab Drug: Pertuzumab Drug: Erlotinib Drug: Vemurafenib […]

Molecular Analysis for Therapy Choice (MATCH) Condition: Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Kidney Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Ovarian Carcinoma, Pancreatic Carcinoma, Plasma Cell Myeloma, Prostate […]